Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
14(64%)
Results Posted
80%(4 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
8
36%
Ph phase_3
7
32%
Ph phase_1
6
27%

Phase Distribution

6

Early Stage

8

Mid Stage

7

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
6(28.6%)
Phase 2Efficacy & side effects
8(38.1%)
Phase 3Large-scale testing
7(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

14

trials recruiting

Total Trials

22

all time

Status Distribution
Active(15)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting8
Recruiting6
Completed5
Terminated1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
14
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (28.6%)
Phase 28 (38.1%)
Phase 37 (33.3%)

Trials by Status

active_not_recruiting836%
recruiting627%
completed523%
terminated15%
unknown15%
not_yet_recruiting15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT05296798Phase 3

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Active Not Recruiting
NCT07054190Phase 2

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Recruiting
NCT05708235Phase 2

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Active Not Recruiting
NCT07643831

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Unknown
NCT07827573Phase 3

A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Not Yet Recruiting
NCT06065748Phase 3

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Active Not Recruiting
NCT05634499Phase 2

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

Completed
NCT07541079Phase 3

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Recruiting
NCT04576455Phase 2

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Active Not Recruiting
NCT04931342Phase 2

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active Not Recruiting
NCT03424005Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Recruiting
NCT07100106Phase 1

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Recruiting
NCT04802759Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Recruiting
NCT07214662Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Terminated
NCT04546009Phase 3

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Active Not Recruiting
NCT04961996Phase 3

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Active Not Recruiting
NCT05306340Phase 3

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Active Not Recruiting
NCT04486352Phase 1

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
NCT05659563Phase 2

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Completed
NCT05896566Phase 2

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22